Caelum Biosciences to be acquired by division of AstraZeneca in $150M deal
September 30, 2021 at 14:52 PM EDT
The deal's value could grow by up to another $350 million if a series of product development milestones are met.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|